Julia J Rucklidge1, Matthew J F Eggleston2, Jeanette M Johnstone3, Kathryn Darling1, Chris M Frampton4. 1. Department of Psychology, University of Canterbury, Christchurch. 2. Canterbury District Health Board, Christchurch, New Zealand. 3. Child and Adolescent Psychiatry, Oregon Health & Science University, Portland, OR, USA. 4. Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
Abstract
BACKGROUND: Evaluation of broad-spectrum micronutrient (vitamins and minerals) treatment for childhood ADHD has been limited to open-label studies that highlight beneficial effects across many aspects of psychological functioning. METHOD: This is the first fully blinded randomized controlled trial of medication-free children (n = 93) with ADHD (7-12 years) assigned to eithermicronutrients (n = 47) or placebo (n = 46) in a 1:1 ratio, for 10 weeks. All children received standardized ADHD assessments. Data were collected from clinicians, parents, participants and teachers across a range of measures assessing ADHD symptoms, general functioning and impairment, mood, aggression and emotional regulation. RESULTS: Intent-to-treat analyses showed significant between-group differences favouring micronutrient treatment on the Clinical Global Impression-Improvement (ES = 0.46), with 47% of those on micronutrients identified as 'much' to 'very much' improved versus 28% on placebo. No group differences were identified on clinician, parent and teacher ratings of overall ADHD symptoms (ES ranged 0.03-0.17). However, according to clinicians, 32% of those on micronutrients versus 9% of those on placebo showed a clinically meaningful improvement on inattentive (OR = 4.9; 95% CI: 1.5-16.3), but no group differences on improvement in hyperactive-impulsive symptoms (OR = 1.0; 95% CI: 0.4-2.5). Based on clinician, parent and teacher report, those on micronutrients showed greater improvements in emotional regulation, aggression and general functioning compared to placebo (ES ranged 0.35-0.66). There were two dropouts per group, no group differences in adverse events and no serious adverse events identified. Blinding was successful with guessing no better than chance. CONCLUSIONS:Micronutrients improved overall function, reduced impairment and improved inattention, emotional regulation and aggression, but not hyperactive/impulsive symptoms, in this sample of children with ADHD. Although direct benefit for core ADHD symptoms was modest, with mixed findings across raters, the low rate of adverse effects and the benefits reported across multiple areas of functioning indicate micronutrients may be a favourable option for some children, particularly those with both ADHD and emotional dysregulation. Trial registered with the Australian New Zealand Clinical Trials Registry ACTRN12613000896774.
RCT Entities:
BACKGROUND: Evaluation of broad-spectrum micronutrient (vitamins and minerals) treatment for childhood ADHD has been limited to open-label studies that highlight beneficial effects across many aspects of psychological functioning. METHOD: This is the first fully blinded randomized controlled trial of medication-free children (n = 93) with ADHD (7-12 years) assigned to either micronutrients (n = 47) or placebo (n = 46) in a 1:1 ratio, for 10 weeks. All children received standardized ADHD assessments. Data were collected from clinicians, parents, participants and teachers across a range of measures assessing ADHD symptoms, general functioning and impairment, mood, aggression and emotional regulation. RESULTS: Intent-to-treat analyses showed significant between-group differences favouring micronutrient treatment on the Clinical Global Impression-Improvement (ES = 0.46), with 47% of those on micronutrients identified as 'much' to 'very much' improved versus 28% on placebo. No group differences were identified on clinician, parent and teacher ratings of overall ADHD symptoms (ES ranged 0.03-0.17). However, according to clinicians, 32% of those on micronutrients versus 9% of those on placebo showed a clinically meaningful improvement on inattentive (OR = 4.9; 95% CI: 1.5-16.3), but no group differences on improvement in hyperactive-impulsive symptoms (OR = 1.0; 95% CI: 0.4-2.5). Based on clinician, parent and teacher report, those on micronutrients showed greater improvements in emotional regulation, aggression and general functioning compared to placebo (ES ranged 0.35-0.66). There were two dropouts per group, no group differences in adverse events and no serious adverse events identified. Blinding was successful with guessing no better than chance. CONCLUSIONS: Micronutrients improved overall function, reduced impairment and improved inattention, emotional regulation and aggression, but not hyperactive/impulsive symptoms, in this sample of children with ADHD. Although direct benefit for core ADHD symptoms was modest, with mixed findings across raters, the low rate of adverse effects and the benefits reported across multiple areas of functioning indicate micronutrients may be a favourable option for some children, particularly those with both ADHD and emotional dysregulation. Trial registered with the Australian New Zealand Clinical Trials Registry ACTRN12613000896774.
Authors: Jeanette M Johnstone; Brenda M Y Leung; Priya Srikanth; Irene Hatsu; Leanna Perez; Barbara Gracious; Gabriella Tost; Michael G Aman; Kenneth D Gadow; Robert L Findling; Oscar Bukstein; L Eugene Arnold Journal: J Child Adolesc Psychopharmacol Date: 2020-02-26 Impact factor: 2.576
Authors: Alisha M Bruton; Angela Senders; Gabriella Tost; Hayleigh Ast; Lisa M Robinette; Brenda Leung; Irene E Hatsu; L Eugene Arnold; Jeanette M Johnstone Journal: Disabil Rehabil Date: 2022-03-10 Impact factor: 2.439
Authors: Jeanette M Johnstone; Irene Hatsu; Gabriella Tost; Priya Srikanth; Leanna P Eiterman; Alisha M Bruton; Hayleigh K Ast; Lisa M Robinette; Madeline M Stern; Elizabeth G Millington; Barbara L Gracious; Andrew J Hughes; Brenda M Y Leung; L Eugene Arnold Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-07-22 Impact factor: 13.113
Authors: Annick Bosch; Margreet Bierens; Ardine G de Wit; Verena Ly; Jessica van der Velde; Heleen de Boer; Gerry van Beek; Danielle Appelman; Sacha Visser; Lisa Bos; Jolanda van der Meer; Niki Kamphuis; Jos M T Draaisma; Rogier Donders; Gigi H H van de Loo-Neus; Pieter J Hoekstra; Marco Bottelier; Alejandro Arias-Vasquez; Helen Klip; Jan K Buitelaar; Saskia W van den Berg; Nanda N Rommelse Journal: BMC Psychiatry Date: 2020-05-27 Impact factor: 3.630
Authors: Rebecca Carnegie; Jie Zheng; Hannah M Sallis; Hannah J Jones; Kaitlin H Wade; Jonathan Evans; Stan Zammit; Marcus R Munafò; Richard M Martin Journal: Lancet Psychiatry Date: 2019-11-20 Impact factor: 27.083